Home Our offer HealthTech

HealthTech

Whether for the development of new drugs, new diagnostic solutions, new medical devices and equipment, or even new services for patients and healthcare providers, innovative medical technologies are at the heart of the reflections on improving healthcare systems; this is the emergence of a universe called HealthTech. The Alcimed Healthcare team supports companies in this sector but also more generally healthcare players in their innovation and development projects related to the HealthTech field.

Contact our team!

HealthTech medtech biotech Consulting firm Experts Specialistschallenges related to HealthTech

  • What is HealthTech?

The HealthTech ecosystem brings together all the companies and start-ups that develop innovative solutions in the health sector. It is possible to differentiate among these players:

  • MedTechs, which develop new medical equipment and devices based on innovative technologies. These include, for example, companies that develop innovative prostheses or manufacturers of devices that automatically regulate insulin levels.
  • BioTechs, which develop new treatments, diagnostics or biological drugs,
  • E-health players, which develop new digital tools or services in the field of healthcare, such as online medical appointment booking services.
  • What are the challenges related to HealthTech?

The HealthTech sector is currently the most dynamic sector of the healthcare market. In France alone, there are more than 2,000 HealthTechs, and among these nearly 750 BioTechs, 1,200 MedTechs and 200 e-health players. In addition, pharma companies, with a more traditional positioning, are also investing in such medical technologies. In 2021 alone, companies in the French HealthTech ecosystem raised €2.3 billion.

However, this exceptional dynamic hides major challenges for companies and healthcare systems, such as:

HealthTech players are players who offer services and products that usually require substantial investments. Access to public funds and/or the attraction of private funds is a key and strategic issue for these companies.

Which public funding window to turn to? How to convince investors, institutional or private?
The regulations for introducing new drugs, devices or medical equipment to the market are very complex and rapidly changing. This is particularly true for Digital Therapeutics, which is a new category of health products, already treated differently between the United States and Europe for example. Marketing authorization, or CE marking, is not the last complex step in market access. Indeed, the care and reimbursement models are far from being established, and it is often up to companies developing HealthTech to offer innovative solutions on this financial aspect as well.

What is the optimal market access route for a given product/service? What innovative business model to create around HealthTech? What acceleration strategy should be proposed to the competent authorities?
Most BioTechs, MedTechs or e-health players are small players, who need several partners, upstream or downstream of the value chain, to carry out their development, from R&D to marketing. In addition, the frenzy of the HealthTech sector leads to a race between players, for funding, for places of experimentation, for access to the market, etc. The speed of development of a HealthTech company is thus key, and well often, it will be linked to its ability to forge solid partnerships, likely to be subsequently integrated.

Which actors offer relevant adjacencies for your product or service? How to distribute the value within a partnership ecosystem? How to build your build-up strategy?

Have a project? Write us!

How do we support you in your HealthTech, MedTech or BioTech projects

Since its creation more than 25 years ago, Alcimed has been supporting many companies in their challenges related to HealthTech. Indeed, we have carried out dozens of projects in this field for different stakeholders such as:

  • BioTechs (such as Actelion, Akcea Therapeutics, Alnylam, Enterome, Insmed, Moderna, Polyplus, Vertex, etc.)
  • MedTechs (such as Arjo, Baxter, GE Healthcare, Johnson & Johnson, Owen Mumford, Rainin, Stryker, Terumo, etc.)
  • E-health players (such as Livi, Cibiltech, MyData-TRUST, WeHealth by Servier, etc.)
  • Industrial players and public actors wishing to have a better understanding of the issues related to these innovative health technologies and wishing to position themselves in this sector.

The diversity of our clients, the geographic fields we explore, and the types of projects we carry out, give us a global and in-depth understanding of the issues addressed in the field of HealthTech.

Our projects cover areas as diverse as seeking funding, preparing for the launch of new drugs, devices or medical equipment, analyzing associated business models, conducting competitive benchmark, identifying key partners, understanding disease management and patient care pathways, assessing market opportunities, market access, pricing and reimbursement, regulatory developments and operational support..

The types of projects we carry out for our clients in this field are:

  • Regulatory framework analysis
  • Innovation consulting
  • Customer experience
  • Commercial strategy
  • Business models
  • Strategic positioning
  • Market study
  • Dossier creation
  • Search for funding opportunities
  • Search for partners
  • Value proposition
  • Roadmap
  • Benchmark
  • Due diligence
  • Go to market
  • Patient pathway
  • Market access
  • New offers
  • Competitive analysis
  • Opportunity evaluation

A project? Contact our explorers!

EXAMPLES OF RECENT PROJECTS CARRIED OUT OF OUR CLIENTS IN THE FIELD OF HEALTHTECH

Alcimed has been supporting an American BioTech specializing in a rare disease for many years in its establishment in Europe.

Our support was focused on several topics. The first, through the exploration and understanding of the ecosystem of different European countries, aimed to understand patient pathways, identify the main care centers, opinion leaders, etc. Subsequently, we helped define the strategy for launching our client's treatment at the European level, with an important medical component given the unmet medical needs for this rare disease, and the lack of structuring of the care systems. Operational launch plans have been developed in key European markets. Finally, we have co-created a care ecosystem for patients through collaborations with opinion leaders, care centers and learned societies, with the objective of improving the level of knowledge, diagnosis and quality of care for patients in the various French centers.
One of our clients wanted to improve the management of chronic diseases for patients requiring assistance from a relative, in particular children and the elderly, using a new medical monitoring device.

Alcimed tested the receptivity of the product's functionalities, its ergonomics, its aesthetics, with different categories of patients, but also with their relatives and caregivers, in order to define more precisely the optimal positioning of the device. At the same time, Alcimed identified the most relevant distribution channels, by patient category. Our client's product was commercialized in 2021.
Alcimed supported a pharmaceutical laboratory in the strategic assessment of several HealthTech start-ups developing digital solutions in pain management, type 2 diabetes treatment, management of neuropsychiatric disorders, etc. Our client wanted to study these start-ups in order to offer them potential partnerships.

Our team’s analyses mainly consisted of evaluating the addressable market for the medical device, evaluating the ability of the company analyzed to establish itself in its competitive environment, and evaluating the receptivity of the solutions by the patients concerned.

The final objective of our project was to conclude on the relevance and viability of the start-ups studied as well as to define their optimal business models, with a view to a strategic alliance with our client.
Alcimed supported a player offering online consultations in its acquisition strategy.

This support began with a scoping of the types of companies interesting for an acquisition with regard to the strategy and prospects of our client. This was followed by a screening of potential target companies and a more detailed characterization of the most promising companies. Most of the companies screened and characterized were MedTechs, BioTechs and e-health players complementary to our client's offering.

Founded in 1993, Alcimed is an innovation and new business consulting firm, specializing in innovation driven sectors: life sciences (healthcare, biotech, agrifood), energy, environment, mobility, chemicals, materials, cosmetics, aeronautics, space and defence.

Our purpose? Helping both private and public decision-makers explore and develop their uncharted territories: new technologies, new offers, new geographies, possible futures, and new ways to innovate.

Located across eight offices around the world (France, Europe, Singapore and the United States), our team is made up of 220 highly-qualified, multicultural and passionate explorers, with a blended science/technology and business culture.

Our dream? To build a team of 1,000 explorers, to design tomorrow's world hand in hand with our clients.

TELL US MORE ABOUT YOUR UNCHARTED TERRITORY

    You have a project and want to discuss it with our explorers, write us ! One of our explorers will contact you shortly.